VMS-986489: No Available Evidence
There is no available evidence for VMS-986489 as an oncology trial drug in the provided literature or in established medical databases.
Search Results
After comprehensive review of the provided evidence base, which includes:
- Multiple ASCO clinical practice guidelines on venous thromboembolism in cancer patients 1
- Treatment guidelines for cancer-associated thrombosis 1
- ESMO guidelines on cancer pain management 1
- SIO-ASCO guidelines on integrative oncology 1
- NCCN-based guidelines on small cell lung cancer treatment 2, 3
- Various research studies on cancer treatments 4, 5, 6, 7, 8
No references to VMS-986489 were identified in any guideline, drug label, or research publication.
Important Clarifications
- The abbreviation "VMS" in the medical literature refers to vasomotor symptoms (hot flashes/night sweats), particularly in cancer survivors 8
- "VMS" also refers to video-mediastinoscopy, a surgical staging procedure for lung cancer 4
- "VM-26" is the designation for teniposide, an established chemotherapy agent used in lymphomas and leukemias 5, 6, 7
Recommendation
If you are seeking information about a specific investigational oncology agent, verify the correct drug name and trial identifier (such as NCT number) to enable accurate evidence retrieval. The designation "VMS-986489" does not correspond to any known oncology therapeutic in current medical literature or clinical trial databases as of the evidence provided.